Patents by Inventor Alan J. Kingsman
Alan J. Kingsman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110269826Abstract: The present invention provides methods for: (i) treating and/or preventing Parkinson's disease in a subject without causing cognitive impairment by using dopamine replacement gene therapy to maintain or restore constant physiological dopaminergic tone in both the dorsal and ventral striatum of the subject; (ii) normalising neuronal electrical activity in basal ganglia and/or subthalamic nucleus in a Parkinson's disease subject; and (iii) treating and/or preventing dyskinesias associated with oral L-dopa administration in a Parkinson's disease subject by administration of a vector system for dopamine replacement gene therapy to the subject.Type: ApplicationFiled: November 11, 2009Publication date: November 3, 2011Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Susan M. Kingsman, Alan J. Kingsman, Scott Ralph, Kyriacos A. Mitrophanous, Stephane Palfi, Bechir Jarraya
-
Publication number: 20080175819Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: ApplicationFiled: August 6, 2007Publication date: July 24, 2008Applicant: Oxford BioMedica (UK) LimitedInventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
-
Patent number: 7276488Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: GrantFiled: January 29, 2002Date of Patent: October 2, 2007Assignee: Oxford Biomedica (UK) LimitedInventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
-
Patent number: 6818209Abstract: A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable or recognising the target site.Type: GrantFiled: November 22, 2000Date of Patent: November 16, 2004Assignee: Oxford Biomedica (UK) LimitedInventors: Kyriacos A. Mitrophanous, Deva Patil, Alan J. Kingsman, Susan M. Kingsman, Fiona M. Ellard
-
Publication number: 20030083290Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.Type: ApplicationFiled: January 29, 2002Publication date: May 1, 2003Inventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
-
Patent number: 6287572Abstract: This invention relates to novel peptides and proteins and nucleic acids encoding them, which are useful against HIV infection. The peptides comprise an amino acid sequence of a part of the HIV-1 p17 protein or of the HIV-2 p16 protein, from amino acid residues 31 to 45 or from amino acid residues 41 to 55. The proteins are recombinant p16 and p17 proteins having an alteration in helix A which is defined by amino acid residues 31 to 46, or the A-B loop which is defined by amino acid residues 47 to 52.Type: GrantFiled: August 24, 1999Date of Patent: September 11, 2001Assignee: Oxford Biomedica (UK) LimitedInventors: Alan J. Kingsman, Susan M. Kingsman, Paula M. Cannon
-
Patent number: 5463024Abstract: Fusion proteins comprise a first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the TYA gene of the yeast retrotransposon Ty. The second amino acid sequence is biologically active; for example it may be antigenic. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.Type: GrantFiled: September 1, 1993Date of Patent: October 31, 1995Assignee: British Biotech Pharmaceuticals LimitedInventors: Alan J. Kingsman, Susan M. Kingsman, Sally E. Adams, Elizabeth J. C. Mellor, Michael H. Malim
-
Patent number: 5041385Abstract: Fusion proteins comprising a first amino acid sequence and a second amino acid sequence are disclosed. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles. The TYA gene of the yeast retrotransposon Ty codes for the first amino acid sequence. The second amino acid sequence is a biologically active antigen. The particles formed by the fusion proteins are useful in vaccines or in diagnostic or purification applications.Type: GrantFiled: April 10, 1987Date of Patent: August 20, 1991Assignee: Oxford Gene Systems LimitedInventors: Alan J. Kingsman, Susan M. Kingsman, Sally E. Adams, Michael H. Malim, Elizabeth-Jane C. Mellor
-
Patent number: 5008373Abstract: Fusion proteins comprise a first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability of assemble into particles; an example is the product of the TYA gene of the yeast retrotransposon Ty. The second amino acid sequence is biologically active; for example, it may be antigenic.Type: GrantFiled: October 26, 1987Date of Patent: April 16, 1991Assignee: Oxford Gene Systems LimitedInventors: Alan J. Kingsman, Susan M. Kingsman, Sally E. Adams, Elizabeth J. C. Mellor, Michael H. Malim
-
Patent number: 4918166Abstract: Fusion proteins comprise a77 first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the YTA gene of the yeast retrotransposon Ty. The second amino acid sequence is an HIV antigen. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.Type: GrantFiled: October 26, 1987Date of Patent: April 17, 1990Assignee: Oxford Gene Systems LimitedInventors: Alan J. Kingsman, Susan M. Kingsman, Sally E. Adams
-
Patent number: 4898823Abstract: An upstream activator sequence derived from the yeast PGK gene. The upstream activator sequence is contained in the 5' region of the yeast PGK gene between nucleotides -324 and -455. The upstream activator sequence has synthetic linkers attached to either end to facilitate attachment to a vector. Vectors including the upstream activator sequence and a heterologous promoter sequence are described. The upstream activator sequence is used in a method for increasing the expression level of a yeast expression vector.Type: GrantFiled: February 29, 1988Date of Patent: February 6, 1990Assignee: Celltech LimitedInventors: Alan J. Kingsman, Susan M. Kingsman
-
Patent number: 4615974Abstract: There are described a number of plasmid vectors suitable for the expression of genetic material, at various levels in yeasts. The plasmids each comprise a yeast selective marker, a yeast replication origin and a yeast promoter positioned relative to a unique restriction site in such a way that expression may be obtained of a polypeptide coding sequence inserted at the restriction site. The promoters used are derived from the 5' region of a gene coding for a yeast glycolytic enzyme e.g. phosphoglycerate kinase (PGK), or from the 5' region of the yeast TRP1 gene. In one Example a plasmid contains a promoter derived from both the 3' and 5' regions of the PGK gene. The replication systems used involve the yeast 2.mu. replication origin or an autonomous replicating sequence (ARS) stabilized with an ARS stabilizing sequence (ASS). The replication systems allow for a choice of high or low copy number per cell. The promoter sequences allow for a choice of high or low expression level.Type: GrantFiled: August 17, 1982Date of Patent: October 7, 1986Assignee: Celltech LimitedInventors: Alan J. Kingsman, Susan M. Kingsman